Cargando…
Novel Triazole-Quinoline Derivatives as Selective Dual Binding Site Acetylcholinesterase Inhibitors
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder worldwide. Currently, the only strategy for palliative treatment of AD is to inhibit acetylcholinesterase (AChE) in order to increase the concentration of acetylcholine in the synaptic cleft. Evidence indicates that AChE also...
Autores principales: | Mantoani, Susimaire P., Chierrito, Talita P. C., Vilela, Adriana F. L., Cardoso, Carmen L., Martínez, Ana, Carvalho, Ivone |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6273213/ https://www.ncbi.nlm.nih.gov/pubmed/26861273 http://dx.doi.org/10.3390/molecules21020193 |
Ejemplares similares
-
Galantamine-Curcumin Hybrids as Dual-Site Binding Acetylcholinesterase Inhibitors
por: Stavrakov, Georgi, et al.
Publicado: (2020) -
Novel Lawsone–Quinoxaline
Hybrids as New Dual
Binding Site Acetylcholinesterase Inhibitors
por: Suwanhom, Paptawan, et al.
Publicado: (2023) -
Co-Immobilized Capillary Enzyme Reactor Based on Beta-Secretase1 and Acetylcholinesterase: A Model for Dual-Ligand Screening
por: Vilela, Adriana Ferreira Lopes, et al.
Publicado: (2021) -
Dual Binding Site and Selective Acetylcholinesterase Inhibitors Derived from Integrated Pharmacophore Models and Sequential Virtual Screening
por: Gupta, Shikhar, et al.
Publicado: (2014) -
7-Methoxytacrine-p-Anisidine Hybrids as Novel Dual Binding Site Acetylcholinesterase Inhibitors for Alzheimer’s Disease Treatment
por: Korabecny, Jan, et al.
Publicado: (2015)